-

Allurion to Present at Jefferies Global Healthcare Conference

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that Dr. Shantanu Gaur, Founder and Chief Executive Officer, will present at the upcoming Jefferies Global Healthcare Conference in New York. The live presentation will take place on Wednesday, June 4 at 3:45 p.m. ET.

A webcast of the presentation will be available in the Events & Presentations section of Allurion’s investor relations website.

About Allurion

Allurion is a pioneer in metabolically healthy weight loss. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-lessTM gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Program, please visit www.allurion.com.

Contacts

Investor / Media Contact
investors@allurion.com

Industry:

Allurion Technologies, Inc.

NYSE:ALUR
Release Versions
English
$Cashtags
$ALUR

Contacts

Investor / Media Contact
investors@allurion.com

More News From Allurion Technologies, Inc.

Allurion Advances Plan to Re-List

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (OTCQB: ALUR), a pioneer in metabolically healthy weight loss, today announced a 1-for-15 reverse stock of its outstanding common stock intended to support regaining compliance with the continued listing requirements of the New York Stock Exchange (the “NYSE”) or initial listing requirements of the NYSE American. Allurion continues to actively engage with national exchanges and is advancing its re-listing strategy as part of a comprehe...

Allurion Announces Strong Start to U.S. Launch with Exceptional Early Outcomes and Growth Momentum

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (OTCQB: ALUR), a pioneer in metabolically healthy weight loss, today announced successful early traction in the launch of the Allurion Program in the United States, marked by strong clinical outcomes, rapid account growth, high re-order rates, and performance exceeding internal expectations. First shipments of the Allurion Smart Capsule were completed in April, with the first U.S. patients treated that same month. Early clinical outcom...

Allurion Treats First Commercial Patients in the United States, Marking Major Milestone

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (OTCID: ALUR), a pioneer in metabolically healthy weight loss, today announced the successful commercial treatment of its first patients in the United States—an inflection point that formally launches the company into the world’s largest and most dynamic obesity market. Allurion is seeing growing demand from patients who have discontinued GLP-1 therapy due to side effects, long-term commitment concerns, or weight regain following disco...
Back to Newsroom